Exploring the Role of At-home Semi-Quantitative Pregnancy Tests for Medical Abortion Follow-up

NCT ID: NCT01150279

Last Updated: 2015-10-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine the feasibility, acceptability and usability of a semi-quantitative urine pregnancy test (dBest One Step hCG Panel Test Kit) for at-home follow-up after early medical abortion using mifepristone+misoprostol. The study seeks to:

1. Assess the feasibility of using this test in lieu of standard one-week clinic-based follow up for determination of complete abortion status as part of normal service delivery. In Mexico, follow up will be in two weeks, as is standard care in that .
2. To determine if women using this test at home understand how to use it and can correctly interpret the results; is it practical.
3. Assess women's and provider's acceptability of using at-home pregnancy tests in lieu of clinic-based follow up for confirmation of complete medical abortion in the future.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Medical Abortion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women age greater than or equal to 18 years
* Gestational age less than or equal to 63 days by last menstrual period (LMP), ultrasound or clinical assessment
* Agrees to return for follow-up visit and willing to provide an address and/or telephone number for purposes of follow-up
* Able to consent to study participation.


* Gestational age \<\_ 70 days from LMP
* Eligible for mifepristone- misoprostol medical abortion according to clinic guidelines
* Willing to follow instructions of the provider regarding use of the at-home pregnancy test
* Agrees to provide test results by phone to study coordinator on morning of schedule follow-up visit
* Willing to provide an address and/or telephone number for purposes of follow-up
* Agrees to return for standard follow-up visit
* Wishes to participate in the study
* Having easy access to a telephone and transportation
* Able to consent to study participation

Exclusion Criteria

* Women less than 18 years of age
* Women not eligible for medical abortion services
* Women unable to provide contact information
* Women unable to sign the consent form


* Women not eligible for medical abortion services
* Women unable to provide contact information
* Women unable to sign the consent form
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Stanford University

OTHER

Sponsor Role collaborator

Secretaría de Salud del Distrito Federal

UNKNOWN

Sponsor Role collaborator

Office National de la Famille et de la Population, Tunisia

UNKNOWN

Sponsor Role collaborator

Maternité de la Rabta, Tunisia

UNKNOWN

Sponsor Role collaborator

Clinique du Parc, Tunisia

UNKNOWN

Sponsor Role collaborator

Gynuity Health Projects

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul D Blumenthal, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Beverly Winikoff, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Gynuity Health Projects

Jennifer Blum, MPH

Role: PRINCIPAL_INVESTIGATOR

Gynuity Health Investigator

Patricio Sanhueza Smith, MD

Role: PRINCIPAL_INVESTIGATOR

Secretaría de Salud del Distrito Federal

Rym Fayala, MD

Role: PRINCIPAL_INVESTIGATOR

Office National de la Famille et de la Population

Ezzedine Sfar

Role: PRINCIPAL_INVESTIGATOR

Maternité de la Rabta

Hella Chelli

Role: PRINCIPAL_INVESTIGATOR

Clinique du Parc

Rasha Dabash, MPH

Role: STUDY_DIRECTOR

Gynuity Health Projects

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stanford University Hospital

Palo Alto, California, United States

Site Status

Planned Parenthood Mar Monte

Sacramento, California, United States

Site Status

Family Planning Associates Group - Washington

Chicago, Illinois, United States

Site Status

Family Planning Associates- Elston

Chicago, Illinois, United States

Site Status

Hospital Materno Infantil Nicolas M. Cedillo

Mexico City, , Mexico

Site Status

ONFP Ben Arous

Ben Arous, , Tunisia

Site Status

ONFP Nabeul

Nabeul, , Tunisia

Site Status

ONFP Sousse

Sousse, , Tunisia

Site Status

Clinique du Parc

Tunis, , Tunisia

Site Status

Maternite de la Rabta

Tunis, , Tunisia

Site Status

HocMon District Hospital

Ho Chi Minh City, , Vietnam

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Mexico Tunisia Vietnam

References

Explore related publications, articles, or registry entries linked to this study.

Dabash R, Shochet T, Hajri S, Chelli H, Hassairi AE, Haleb D, Labassi H, Sfar E, Temimi F, Koenig L, Winikoff B. Self-administered multi-level pregnancy tests in simplified follow-up of medical abortion in Tunisia. BMC Womens Health. 2016 Jul 30;16:49. doi: 10.1186/s12905-016-0327-1.

Reference Type DERIVED
PMID: 27475998 (View on PubMed)

Lynd K, Blum J, Ngoc NT, Shochet T, Blumenthal PD, Winikoff B. Simplified medical abortion using a semi-quantitative pregnancy test for home-based follow-up. Int J Gynaecol Obstet. 2013 May;121(2):144-8. doi: 10.1016/j.ijgo.2012.11.022. Epub 2013 Mar 7.

Reference Type DERIVED
PMID: 23477704 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

6.1.3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.